Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients

NCT04603924 is registered in ClinicalTrials.gov with NeuroBo Pharmaceuticals Inc. as lead sponsor.

NCT NCT04603924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04603924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
October 7, 2020
Completion date
February 16, 2022
Enrollment
49 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19